Editorial: Gene Expression Profile Assays As an Aid in Treatment Decision Making in Early-stage Breast Cancer

Overview

Journal J Oncol Pract

Specialty Oncology

Date 2010 Sep 23

PMID 20859408

Authors

Gary H Lyman

Affiliations

Soon will be listed here.

References

Simon R, Radmacher M, Dobbin K, McShane L . Pitfalls in the use of DNA microarray data for diagnostic and prognostic classification. J Natl Cancer Inst. 2003; 95(1):14-8. DOI: 10.1093/jnci/95.1.14. View

Paik S, Shak S, Tang G, Kim C, Baker J, Cronin M . A multigene assay to predict recurrence of tamoxifen-treated, node-negative breast cancer. N Engl J Med. 2004; 351(27):2817-26. DOI: 10.1056/NEJMoa041588. View

Lyman G, Kuderer N . Gene expression profile assays as predictors of recurrence-free survival in early-stage breast cancer: a metaanalysis. Clin Breast Cancer. 2007; 7(5):372-9. DOI: 10.3816/CBC.2006.n.053. View

Fisher B, Jeong J, Bryant J, Anderson S, Dignam J, Fisher E . Treatment of lymph-node-negative, oestrogen-receptor-positive breast cancer: long-term findings from National Surgical Adjuvant Breast and Bowel Project randomised clinical trials. Lancet. 2004; 364(9437):858-68. DOI: 10.1016/S0140-6736(04)16981-X. View

Paik S, Tang G, Shak S, Kim C, Baker J, Kim W . Gene expression and benefit of chemotherapy in women with node-negative, estrogen receptor-positive breast cancer. J Clin Oncol. 2006; 24(23):3726-34. DOI: 10.1200/JCO.2005.04.7985. View

. Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: an overview of the randomised trials. Lancet. 2005; 365(9472):1687-717. DOI: 10.1016/S0140-6736(05)66544-0. View

Broeckel J, Jacobsen P, Balducci L, Horton J, Lyman G . Quality of life after adjuvant chemotherapy for breast cancer. Breast Cancer Res Treat. 2000; 62(2):141-50. DOI: 10.1023/a:1006401914682. View

Hornberger J, Cosler L, Lyman G . Economic analysis of targeting chemotherapy using a 21-gene RT-PCR assay in lymph-node-negative, estrogen-receptor-positive, early-stage breast cancer. Am J Manag Care. 2005; 11(5):313-24. View

Oratz R, Paul D, Cohn A, Sedlacek S . Impact of a commercial reference laboratory test recurrence score on decision making in early-stage breast cancer. J Oncol Pract. 2010; 3(4):182-6. PMC: 2793805. DOI: 10.1200/JOP.0742001. View

10.

Altman D, Lyman G . Methodological challenges in the evaluation of prognostic factors in breast cancer. Breast Cancer Res Treat. 1999; 52(1-3):289-303. DOI: 10.1023/a:1006193704132. View

11.

Earle C, Chapman R, Baker C, Bell C, Stone P, Sandberg E . Systematic overview of cost-utility assessments in oncology. J Clin Oncol. 2000; 18(18):3302-17. DOI: 10.1200/JCO.2000.18.18.3302. View

12.

Cronin M, Pho M, Dutta D, Stephans J, Shak S, Kiefer M . Measurement of gene expression in archival paraffin-embedded tissues: development and performance of a 92-gene reverse transcriptase-polymerase chain reaction assay. Am J Pathol. 2003; 164(1):35-42. PMC: 1602211. DOI: 10.1016/S0002-9440(10)63093-3. View

13.

Lyman G, Cosler L, Kuderer N, Hornberger J . Impact of a 21-gene RT-PCR assay on treatment decisions in early-stage breast cancer: an economic analysis based on prognostic and predictive validation studies. Cancer. 2007; 109(6):1011-8. DOI: 10.1002/cncr.22506. View

14.

Jemal A, Siegel R, Ward E, Murray T, Xu J, Smigal C . Cancer statistics, 2006. CA Cancer J Clin. 2006; 56(2):106-30. DOI: 10.3322/canjclin.56.2.106. View